Helixgate https://validator.w3.org/feed/docs/rss2.html STAT+: Former Madrigal Pharmaceuticals executive alleges coverup of safety issues tied to its drug Biopharma likely to climb higher after ‘blue wave,’ analysts say Radiopharma venture money moves toward alpha emitters FDA needs a roadmap for disease-agnostic drug development — a Perspective Caspian: Regenerating beta cells with a menin inhibitor With Vidya acquisition, Gujrathi takes chair role at Processa FDA approves first DNA plasmid immunotherapy; NME tally reaches 47 Molecular imaging reveals how shape-shifting protein complex captures DNA and holds separate sections together AlphaFold 3 predicts complex immune interactions using protein sequences alone STAT+: Pharmalittle: We’re reading about CVS plans to split up, FDA inspections in India and China and more STAT+: Ultragenyx cuts staff after another study fails  STAT+: Pharma critic Bernie Sanders is set to hold major sway over FDA funding bill Standardized Apheresis Processes Would Help Cell Therapy Sector Small Bioprocess Monitoring Hits the Goldilocks Zone Rethinking the Clone-First Paradigm for First-in-Human Biologics HIV-Blocking Antibody Shows Promise, but Resistant Strains Break Through Building Custom DNA without Bacterial Constraints Gene That Preserves Bone Stem Cell Supply Throughout Life Identified As Therapeutic Modalities Expand, Genomic Profiling Must Keep Pace Multiomic Human Glioblastoma Cell Atlas Could Act as Compass to Guide Future Treatment Approaches Lonza Expanding U.S. CDMO Footprint with Purchase of Five Merck KGaA Sites Beyond Outsourcing: Building Better CDMO Partnerships Most nurses at Ugandan hospital miss at least one of the Five Rights of antimicrobial administration, survey finds Anti-CGRP Migraine Drugs Cut Monthly Headache Days by Nearly Half in Catalan Cohort TACMONO-XL trial to test whether tacrolimus monotherapy can cut infections in older kidney transplant recipients PACE panel notes challenges IRA poses for patients STAT+: Servier’s $1.55 billion muscular dystrophy drug fails first major test A push for speedier drug approvals doesn’t promise smooth market sailing Editor’s Pick: Wild Bioscience Q3 earnings roll on, FDA pushes rare disease, uniQure’s Huntington’s therapy reaches review Sanofi’s axing of Nurix STAT6 program ‘not a target-related issue’ Amgen starts MariTide autoinjector study as pivotal readouts approach AbbVie bets up to $1.47B for Nxera’s discarded IBD program 2026 IPO stock tracker: How newly public biotechs are performing EVERSANA builds its AI Agency with Estima acquisition Case study backs YolTech’s AATD gene therapy German sites added to Europe’s cardiometabolic R&D network Karyopharm files for bankruptcy, looks to merger with Ayrmid for life raft Pfizer flat in Q3 despite 32% growth for new and acquired products Neurocrine defends Prader-Willi drug after another patient death Lonza agrees to buy 5 Merck KGaA facilities to accelerate US expansion Compass to submit psilocybin depression drug for approval imminently after stock wobbles Pfizer, fresh to China’s obesity market, looks to Viagra model to compete 6 potential blockbusters that could pave China’s path to 2030 ambitions Importing Drugs with a Pre-Launch Activities Importation Request (PLAIR) Questions and Answers on Current Good Manufacturing Practice Regulations | Production and Process Controls Advancing Generic Drug Development: Bioequivalence Challenges for Patient-Centric Oral Formulations – 06/11/2026 How to Register a Drug Establishment What’s New in Regulatory Science Home